Brief: Hofseth Biocare ASA: HBC Has Begun Protocol Development For Its Accelerated Phase 2 Clinical Trial

Hofseth Biocare ASA

26/05/2020 07:08

May 26 (Reuters) - Hofseth Biocare ASA  HOFBC.OL :
    * REG-HOFSETH BIOCARE ASA: HBC HAS BEGUN PROTOCOL DEVELOPMENT FOR ITS ACCELERATED PHASE 2
CLINICAL
TRIAL WITH OMEGO® TO DECREASE ACUTE RESPIRATORY DISTRESS SYNDROME AND THE NEED FOR ASSISTED
RESPIRATION IN COVID-19 PATIENTS
    * HOFSETH BIOCARE ASA - IS PREPARING AN INVESTIGATIONAL PROTOCOL WITH KGK SCIENCE INTO
HEALTH
CANADA TO CONDUCT A PHASE 2 CLINICAL TRIAL ASSESSING OMEGO® IN FORM OF OUR BRANDED PRODUCT
CARDIO SOFT GELS AS TREATMENT FOR PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
CAUSED BY SARS-COV-2 VIRUS
    * HOFSETH BIOCARE ASA - TREATMENT WILL FOCUS ON FORMER SMOKERS AND STEROID-RESISTANT ASTHMA
PATIENTS ("PATIENTS"), WHO EXHIBIT EARLY NON-ACUTE LUNG INJURY CAUSED BY SARS-COV-2 VIRUS
    * HOFSETH BIOCARE ASA - TRIAL IS BEING INITIALLY FUNDED FROM HBC'S EXISTING RESEARCH AND
DEVELOPMENT BUDGET FOR 2020.

Source text for Eikon:  ID:nGNE8HpgxJ 
Further company coverage:  HOFBC.OL 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))